Carlisle Companies Inc <CSL.N>: Raymond James cuts target price to $410 from $425
CSL•Related News
Aprea Therapeutics Provides Acesot-1051 Program Update For Wee1 Inhibitor Apr-1051 Accelerating And Expanding Enrollment. Clinical Data Presentation Planned For Q4 2026
APRE•
Mastercard profit jumps as stable spending drives transaction volumes
MA•
Capricor Therapeutics Inc. <CAPR.O>: Oppenheimer cuts to Perform from Outperform
CAPR•
LKQ cuts annual profit forecast on softer auto parts demand in Europe
LKQ•
Curis Doses First Five Patients In Takeaim CLL Study
CRIS•